Biophytis S.A. (ALBPS.PA)
EUR 0.17
(-0.7%)
EUR 0.17
(-0.7%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.11 Million EUR | -28.76% |
| 2022 | 4.36 Million EUR | -30.61% |
| 2021 | 6.29 Million EUR | 243.32% |
| 2020 | 1.83 Million EUR | -66.04% |
| 2019 | 5.39 Million EUR | -15.43% |
| 2018 | 6.38 Million EUR | 801.55% |
| 2017 | 708 Thousand EUR | -22.54% |
| 2016 | 914 Thousand EUR | 126.58% |
| 2015 | 403.39 Thousand EUR | -24.85% |
| 2014 | 536.8 Thousand EUR | 62.47% |
| 2013 | 330.39 Thousand EUR | 8.35% |
| 2012 | 304.93 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 709 Thousand EUR | 0.0% |
| 2024 Q1 | 709 Thousand EUR | -77.21% |
| 2023 FY | 3.11 Million EUR | -28.76% |
| 2023 Q1 | 3.72 Million EUR | -14.79% |
| 2023 Q2 | 3.16 Million EUR | -15.02% |
| 2023 Q4 | 3.11 Million EUR | -4.19% |
| 2023 Q3 | 3.24 Million EUR | 2.69% |
| 2022 Q2 | 4.3 Million EUR | -14.18% |
| 2022 Q4 | 4.36 Million EUR | 0.0% |
| 2022 FY | 4.36 Million EUR | -30.61% |
| 2022 Q3 | 4.36 Million EUR | 1.46% |
| 2022 Q1 | 5.01 Million EUR | -20.31% |
| 2021 Q3 | 5.51 Million EUR | 383.61% |
| 2021 FY | 6.29 Million EUR | 243.32% |
| 2021 Q1 | 1.14 Million EUR | -37.75% |
| 2021 Q2 | 1.14 Million EUR | 0.0% |
| 2021 Q4 | 6.29 Million EUR | 14.04% |
| 2020 Q3 | 1.83 Million EUR | -50.9% |
| 2020 Q1 | 3.73 Million EUR | -15.0% |
| 2020 Q2 | 3.73 Million EUR | 0.0% |
| 2020 Q4 | 1.83 Million EUR | 0.0% |
| 2020 FY | 1.83 Million EUR | -66.04% |
| 2019 FY | 5.39 Million EUR | -15.43% |
| 2019 Q3 | 5.39 Million EUR | -20.75% |
| 2019 Q1 | 7.51 Million EUR | 17.8% |
| 2019 Q4 | 4.39 Million EUR | -18.64% |
| 2019 Q2 | 6.81 Million EUR | -9.42% |
| 2018 Q4 | 6.38 Million EUR | 0.0% |
| 2018 FY | 6.38 Million EUR | 801.55% |
| 2018 Q3 | 6.38 Million EUR | 536.39% |
| 2018 Q2 | 1 Million EUR | 0.0% |
| 2018 Q1 | - EUR | -100.0% |
| 2017 Q4 | 708 Thousand EUR | 0.0% |
| 2017 FY | 708 Thousand EUR | -22.54% |
| 2017 Q1 | 858 Thousand EUR | -6.13% |
| 2017 Q2 | 858 Thousand EUR | 0.0% |
| 2017 Q3 | 708 Thousand EUR | -17.48% |
| 2016 Q1 | 318 Thousand EUR | -21.17% |
| 2016 Q4 | 914 Thousand EUR | 0.11% |
| 2016 FY | 914 Thousand EUR | 126.58% |
| 2016 Q3 | 913 Thousand EUR | 187.11% |
| 2016 Q2 | 318 Thousand EUR | 0.0% |
| 2015 Q3 | 403 Thousand EUR | 26.6% |
| 2015 Q1 | 318.32 Thousand EUR | -40.7% |
| 2015 FY | 403.39 Thousand EUR | -24.85% |
| 2015 Q4 | 403.39 Thousand EUR | 0.1% |
| 2015 Q2 | 318.32 Thousand EUR | 0.0% |
| 2014 Q3 | 536.8 Thousand EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q4 | 536.8 Thousand EUR | 0.0% |
| 2014 FY | 536.8 Thousand EUR | 62.47% |
| 2013 FY | 330.39 Thousand EUR | 8.35% |
| 2012 FY | 304.93 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -182.561% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 93.04% |
| Adocia SA | 4.54 Million EUR | 31.476% |
| Aelis Farma SA | 2.04 Million EUR | -51.904% |
| Advicenne S.A. | 15.89 Million EUR | 80.429% |
| genOway Société anonyme | 5.51 Million EUR | 43.634% |
| IntegraGen SA | 642.28 Thousand EUR | -384.368% |
| Medesis Pharma S.A. | 1.2 Million EUR | -159.25% |
| Neovacs S.A. | 650 Thousand EUR | -378.615% |
| NFL Biosciences SA | 39.2 Thousand EUR | -7835.617% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 28.59% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -58.698% |
| Sensorion SA | 1.24 Million EUR | -150.703% |
| Theranexus Société Anonyme | 2.46 Million EUR | -26.427% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 20.19% |
| TheraVet SA | 1 Million EUR | -210.914% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 54.952% |
| DBV Technologies S.A. | 4.52 Million USD | 31.264% |
| Genfit S.A. | 62.25 Million EUR | 95.003% |
| GeNeuro SA | 6.49 Million EUR | 52.082% |
| Innate Pharma S.A. | 30.6 Million EUR | 89.836% |
| Inventiva S.A. | 25.61 Million EUR | 87.855% |
| MaaT Pharma SA | 5.42 Million EUR | 42.654% |
| MedinCell S.A. | 52.8 Million EUR | 94.108% |
| Nanobiotix S.A. | 41.66 Million EUR | 92.532% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 91.239% |
| Poxel S.A. | 40.14 Million EUR | 92.25% |
| GenSight Biologics S.A. | 1.04 Million EUR | -196.851% |
| Transgene SA | 17 Thousand EUR | -18200.0% |
| Valneva SE | 132.76 Million EUR | 97.657% |